{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-002394","form_type":"8-K","ticker":"EXOZ","cik":"0002010788","company_name":"EXOZYMES INC.","filed_at":"2025-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.677983+00:00","generated_at":"2026-05-24T00:06:49.338900+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"eXoZymes appoints Damien Perriman as CCO to lead commercial growth","bullets":["Damien Perriman appointed to newly created CCO role, effective April 2, 2025.","Perriman brings 20+ years experience commercializing biotechnologies; previously at Genomatica (Geno) and Gevo.","Focus on commercial opportunities, spin-outs, joint ventures, and licensing deals with future partners.","CEO Michael Heltzen: hire reflects strategic focus on scaling and commercializing biosolutions across multiple sectors."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-002394","json":"https://secwatch.observer/filing/0001641172-25-002394.json","markdown":"https://secwatch.observer/filing/0001641172-25-002394.md","text":"https://secwatch.observer/filing/0001641172-25-002394.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2010788/000164117225002394/0001641172-25-002394-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2010788/000164117225002394/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T00:06:49.338900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}